At Fluxion, we’re passionate about delivering cell-based and cell-free solutions that facilitate the transformation of research discoveries into new ways to diagnose and treat patients. By characterizing molecular and cellular mechanisms of disease, Fluxion’s platforms help bridge the translational medicine gap, enabling rapid advances in disease research, drug discovery, and the development of diagnostic tests.
Stanford will utilize Fluxion’s IsoFlux System for patient monitoring and early cancer characterization of prostate and kidney cancers via a “liquid biopsy” from a routine blood draw
SOUTH SAN FRANCISCO, Calif. -- Fluxion Biosciences, Inc. announced today that it has initiated a collaboration with the Stanford University School of Medicine focused on developing tests to help deliver more effective therapies to cancer patients. The laboratory of Dr. James Brooks is utilizing Fluxion’s IsoFlux System to isolate, recover, and analyze rare circulating cancer cells at the molecular level.
Circulating tumor cells (CTCs) disseminate from primary tumors and enter the peripheral bloodstream. Ongoing access to cancer tissue represents one of the most significant challenges in characterizing cancer, and CTCs can alleviate this limitation by providing frequent, minimally-invasive access to cancer tissue via a blood draw. The IsoFlux System uses blood to perform a real-time “liquid biopsy” of the patient’s cancer using the recovered CTCs. The high efficiency and high purity of the recovered cells allows for the use of highly multiplexed analyses such as next-generation sequencing (NGS) for cancer mutational profiling. This allows screening for a broad range of cancer biomarkers that will help guide treatment decisions using an emerging class of precision cancer therapies.
The collaboration with Stanford will focus on prostate and kidney pathologies. The research is designed to help subtype different forms of the disease and develop more effective treatments tailored to each patient. “We are very excited to be working with Dr. Brooks and Dr. Zulfiqar Gulzar on this project,” commented Dr. Cristian Ionescu-Zanetti, CTO of Fluxion. “Cancer is a dynamic disease, and the ability to track changes in each patient via a blood sample can allow actionable changes to be detected much earlier. Dr. Brooks is widely respected as a leader in the field of personalized cancer therapy, and we are delighted to be collaborating with him and his colleagues at Stanford. One aim of the collaboration is to identify markers that can help stratify patients requiring more aggressive treatment from those that don’t. This is currently a major challenge in the treatment of prostate cancer. ”
For more information about the IsoFlux System, please visit www.fluxionbio.com/isoflux.
About Fluxion Biosciences
Fluxion Biosciences provides cellular analysis tools for use in critical life science, drug discovery, and diagnostic applications. Products include the BioFlux™ System for studying cellular interactions, the IonFlux™ System for high throughput patch clamp measurements, and the IsoFlux™ System for circulating tumor cell analysis. Fluxion’s systems are designed to replace laborious and difficult assays by providing intuitive, easy-to-use instruments for cell-based analysis. For more information about Fluxion Biosciences, visit www.fluxionbio.com.
Jeff Jensen CEO Fluxion Biosciences, Inc. 1 (650) 241-4747 email@example.com